Podcasts about Teratoma

Dr. Pedro Barata and Dr. Aditya Bagrodia discuss the evolving landscape of testicular cancer survivorship, the impact of treatment-related complications, and management strategies to optimize long-term outcomes and quality of life. TRANSCRIPT:  Dr. Pedro Barata: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I'm Dr. Pedro Barata. I'm a medical oncologist at University Hospitals Seidman Cancer Center and associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. We all know that testicular cancer is a rare but highly curable malignancy that mainly affects young men. Multimodal advances in therapy have resulted in excellent cancer specific survival, but testicular cancer survivors face significant long term treatment related toxicities which affect their quality of life and require surveillance and management. With that, I'm very happy today to be joined by Dr. Aditya Bagrodia, a urologic oncologist, professor, and the GU Disease Team lead at UC San Diego[KI1]  Health, and also the lead author of the recently published paper in the ASCO Educational Book titled, "Key Updates in Testicular Cancer: Optimizing Survivorship and Survival." And he's also the host of the world-renowned BackTable Urology Podcast. Dr. Bagrodia, I'm so happy that you're joining us today. Welcome. Dr. Aditya Bagrodia: Thanks, Pedro. Absolutely a pleasure to be here. Really appreciate the opportunity. Dr. Pedro Barata: Absolutely.  So, just to say that our full disclosures are available in the transcript of this episode.  Let's get things started. I'm really excited to talk about this. I'm biased, I do treat testicular cancer among other GU malignancies and so it's a really, really important topic that we face every day, right? Fortunately, for most of these patients, we're able to cure them. But it always comes up the question, "What now? You know, scans, management, cardio oncology, what survivorship programs we have in place? Are we addressing the different survivorship piece, psychology, fertility, et cetera?" So, we'll try to capture all of that today. Aditya, congrats again, you did a fantastic job putting together the insights and thoughts and what we know today about this important topic. And so, let's get focused specifically about what happens when patients get cured. So, many of us, in many centers, were fortunate enough to have these survivorship programs together, but I find that sometimes from talking to colleagues, they're not exactly the same thing and they don't mean the same thing to different people, to different institutions, right? So, first things first. What do you tell a patient perhaps when they ask you, "What can happen to me now that I'm done with treatment for testicular cancer?" Whether it's chemotherapy or just surgery or even radiation therapy? "So, what about the long term? What should I expect, Doctor, that might happen to me in the long run?" Dr. Aditya Bagrodia: Totally. I mean, I think that question's really front and center, Pedro, and really appreciate you all highlighting this topic. It was an absolute honor to work with true thought leaders and the survivorship bit of it is front and center, in my opinion. It's really the focus, you know, we, generally speaking should be able to cure these young men, but it's the 10, 15, 20 years down the way that they're going to largely contend with. The conversation really begins at diagnosis, pre-education. Fortunately, the bulk of patients that present are those with stage one disease, and even very basic things like before orchiectomy, talking about a prosthetic; we know that that can impact body image and self esteem, whether or not they decide to receive it or not. Actually, just being offered a prosthetic is important and this is something, you know, for any urologist, it's kind of critical. To discussing fertility elements to this, taking your time to examine the contralateral testicle, ask about fertility problems, issues, concerns, offer sperm banking, even in the context of a completely normal contralateral testicle, I think these things are quite important.  So if it's somebody with stage one disease, you know, without going too far down discussing adjuvant therapy and so forth, I will start the conversation with, "You know, the testes do largely two things. They make testosterone and they make sperm." By and large, patients are going to be able to have acceptable levels of testosterone, adequate sperm parameters to maintain kind of a normal gonadal state and to naturally conceive, should that be something they're interested in. However, there's still going to be, depending on what resource you look at, somewhere in the order of 10-30% that are going to have issues. Where I think for the stage one patients, it's really incumbent upon us is actually to not wait for them to discuss their concerns, particularly with testosterone, which many times can be a little bit vague, but to proactively ask about it every time. Libido, erectile quality, muscle mass maintenance, energy, fatigue. All of these are kind of associated symptoms of hypogonadism. But for a lot of kids 18-20 years old, it's going to be something insidious that they don't think about. So, for the stage one patients, it absolutely starts with gonadal function. If they are stage two getting surgery, I think the counseling really needs to center around a possibility for ejaculatory dysfunction. Now, for a chemotherapy-naive, nerve-sparing RPLND, generally these days we should be able to preserve ejaculatory function at high volume centers, but you still want to bring that up and again kind of touch base on thinking about sperm banking and so forth before the operation, scars, those are things I think worth talking about, small risk of ascites. Then, I think the intensity of potential long term adverse effects really ramps up when we're talking about systemic therapy, chemotherapy. And then there's of course some radiation therapy specific elements that come up. So, for the chemotherapy bits of it, I really think this is going to be something that can be a complete multi-system affected intervention. So, anxiety, depression, our group has actually shown using some population resources that even suicidality can be increased among patients that have been treated for germ cell tumor. You know, really from the top down, tinnitus, hearing changes, those are things that we need to ask about at every appointment. Neuropathy, sexual health, that we kind of talked about, including ED (erectile dysfunction), vertigo, dizziness, Raynaud's phenomenon, these are kind of more the symptoms that I think we need to inquire about every time. And what we do here and I think at a lot of survivorship programs is use kind of a battery of validated instruments, germ cell tumor specific, platinum treated patient specific. So we use a combination of EORTC questions and PROMIS questions, which actually serves as like a review of systems for the patient, also as a research element. We review that and then depending on what might be going on, we can dig into that further, get them over to colleagues in audiology or psychology, et cetera.  And then of course, screening for the hypertension, hyperlipidemia, metabolic syndrome with basically you or myself or somebody kind of like us serving, many times it's the role of the PCP, just making sure we're checking out, you know, CBC, CMP, et cetera, lipid parameters to screen for those kind of cardiac associated issues along with secondary malignancies. Dr. Pedro Barata: So that's super comprehensive and thorough. Thank you so much. Actually, I love how you break it down in a simple way. Two functions of the testes, produce testosterone and then, you know, the problem related to that is the hypogonadism, and then the second, as you mentioned, produce sperm and of course related to the fertility issues with that.  So, let's start with the first one that you mentioned. So, you do cite that in your paper, around 5-10% of men end up getting, developing hypogonadism, maybe clinical when they present with symptoms, maybe subclinical. So, I'm wondering, for our audience, what kind of recommendations we would give for addressing that or kind of thinking of that? How often are you ordering those tests? And then, when you're thinking about testosterone replacement therapy, is that something you do immediately or are there any guidelines into context that? How do you approach that? Dr. Aditya Bagrodia: So, just a bit more on digging into it even in terms of the questions to ask, you know, "Do you have any decrease in sexual drive? Any erectile dysfunction? Are your morning erections still taking place? Has the ejaculate volume changed? Physically, muscle mass, strength? Have you been putting on weight? Have you noticed increase in body fat?" And sometimes this is complicated because there's some anxiety that comes along with a cancer diagnosis when you're 20, 30 years old, multifactorial, hair loss, hot flashes, irritability. Sometimes they'll, you know, literally they'll say, "You know, my significant other or partners noticed that I'm really just a little bit labile." So I think, you know, there's the symptoms and then checking, usually kind of a gonadal panel, FSH, LH, free and total testosterone, sex hormone binding globulin, that's going to be typically pretty comprehensive. So if you've got symptoms plus some laboratory work, and ideally that pre-orchiectomy testosterone gives you some delta. If they started out at an 800, 900, now they're 400, that might be a big change for them. And then, when you talk about TRT (Testosterone Replacement Therapy) recommendations, you know, Pedro, yourself, myself, we're kind of lucky to be at academic centers and we've got men's health colleagues that are ultra experts, but at a high level, I would say that a lot of the TRT options center around fertility goals. Exogenous testosterone treats the low T, but it does suppress gonadal function, including spermatogenesis. So if that's not a priority, they can just get TRT. It should be done under the care of a urologist, a men's health, an endocrinologist, where we're checking liver chemistries and CBCs and a PSA and so forth. If they're interested in fertility preservation, then I would say engaging an endocrinologist, men's health expert is important. There's medications even like hCG, Clomid, which works centrally and stimulate the gonadal access. Niche scenarios where they might want standard TRT now, and then down the way, 5, 7 years, they're thinking about coming off of that for fertility purposes, I think that's really where you want to have an expert involved because there's quite a bit of nuance there in recovery of actual spermatogenesis and so forth.  To kind of summarize, you got to ask about it. Checking it is, is not overly complicated. We do a baseline pre-orchiectomy and at least once annually, you can tag it in with the tumor markers, so it's not an extra blood draw. And if they have symptoms of course, kind of developed, then we'll move that up in the evaluation. Dr. Pedro Barata: Got it. And you also touch base on the fertility angle, which is truly important. And I'm just curious, you know, a lot of times many of us might see one, two patients a year, right, and we forget these protocols and what we've got to do about that.  And so I'm interested to hear your thoughts about when you think about fertility, and how proactive you get. In other words, who do you refer for the fertility clinic, for a fertility preservation program? You know, do all cases despite getting through orchiectomy or just the cases that you're going to, you know you're going to seek chemotherapy at some point? What kind of selection or it depends on the chemo, like how do you do that assessment about the referral for preservation program that you might have available at UCSD? Dr. Aditya Bagrodia: Yeah, I mean I feel really fortunate to sit on the NCCN Testis Cancer Guidelines. It's in there that fertility counseling should be discussed prior to orchiectomy. So 100% bring it up. If there are risk factors, undescended testicles, previous history of fertility concerns, atrophic contralateral testicle, anything on the ultrasound like microlithiasis in the contralateral testicle, you kind of wanna get it there. And then again, there's kind of niche scenarios where you're really worried, maybe get a semen analysis and it doesn't look that good, arrange for the time of orchiectomy to have onco-testicular sperm extraction from the, quote unquote, "normal" testis parenchyma. You know, I think you have to be kind of prepared to go that route and really make sure you're doing this completely comprehensively.  So pre-orchiectomy all patients. Don't really push for it too hard if they've got a contralateral testicle, if they've had no issues having children. There's some cost associated with this, sperm banking still isn't kind of covered even in the context of men with cancer. If they've got risk factors, absolutely pre-orchiectomy. Pre-RPLND, even though the rates of ejaculatory dysfunction at a high-volume center should be low single digits, I'll still offer it. That'd be a real catastrophe if they were in that small proportion of patients and now they're going to be reliant on things like intrauterine insemination, where it becomes quite expensive.  Pre-chemo, everybody. That's basically a standard these days where it should be discussed and it's kind of amazing currently, even if you don't have an accessible men's health fertility clinic, there are actually companies, I have no vested interest, Fellow is one such company where you can actually create an account, receive a FedEx semen analysis and cryopreservation kit, send it back in, and all CLIA certified, it's based out of California. The gentleman that runs it, is a urologist and very, very bright guy who's done a lot of great stuff for testis cancer. So, even for patients that are kind of in extremis at the hospital that kind of need to get going like yesterday, we still discuss it. We've got some mechanisms in place to either have them take a semen analysis over to our Men's Health clinic or send it off to Fellow, which I think is pretty cool and that even extends to some of our younger adolescent patients where going to a clinic and providing a sample might be tricky.  So, I think bringing it up every stage, anytime there's an intervention that might be offered, orchiectomy, chemo, surgery, radiation, it's kind of incumbent on us to discuss it. Dr. Pedro Barata: Gotcha. That's super helpful. And you also touch base on another angle, which is the psychosocial angle around this. You mentioned suicidal rates, you mentioned anxiety, perhaps depression in some cases as well as chronic fatigue, not necessarily just because of the low testosterone that you can get, but also from a psychological perspective. I'm curious, what do the recommendations look like for that? Do these patients need to see a social worker or a psychologist, or do they need to answer a screening test every time they come to see us and then based on that, we kind of escalate, take the next steps according to that? Do they see a psychologist perhaps every so often? How should that be managed and addressed? Dr. Aditya Bagrodia: It's an excellent question and again, these can be rather insidious symptoms where if you don't really dig in and inquire, they can be glossed over. I mean, how easy to say, "Your markers look okay, your scans look okay. See you in six months," and keep it kind of brief. First off, I think bringing it up proactively and normalizing it, that, "This may be something that you experience. Many people do, you're not alone, there's nothing kind of wrong with you." I also think that this is an area where support groups can be incredibly useful. We host the Testicular Cancer Awareness Foundation support group here. They'll talk about chemo brain or just like a little bit of an adjustment disorder after their diagnosis. Support groups, I think are critical. As I mentioned, we have a survivorship program that's led by a combination of our med oncs, myself on the uro-onc side, as well as APPs, where we are systematically asking about essentially the whole litany of issues that may arise, including psychosocial, anxiety, depression, suicidality. And we've got a nice kind of fast path into our cancer center support services for these young men to meet with a psychologist. If that isn't going to be sufficient, they can actually see a psychiatrist to discuss medications and so forth. I do think that we've got to screen for these because, as anticipated from diagnosis, those first 2 years, we see a rise. But even 10, 15 years out, we note, compared to controls, that there is an increased level of anxiety, depression, suicidality that might not just take place at that initial acute period of diagnosis and treatment. Dr. Pedro Barata: Really well said. Super important.  So I guess if I were to put all these together, with these really amazing advances in technology, we all know AI, some of us might be more or less aware of biomarkers coming up, including microRNA for example, and others, like as I think of all these potential long term complications for these patients, look at the future, I guess, can we use this as a way to deescalate treatment where it's not really necessary, as a way to actually prevent some of these complications? Like, how do we see where we're heading? As we manage testicular cancer, let's say, within the next 5 or 10 years, do you think there's something coming up that's going to be different from what we're doing things today? Dr. Aditya Bagrodia: Totally. I mean, I think it's as exciting as a time as there's ever been, you know, maybe notwithstanding circa 1970s when platinum was discovered. So microRNAs, which you mentioned, you know, there's a new candidate biomarker, microRNA-371. We are super excited here at UCSD. We actually have it CLIA-certified available in our lab and are ordering these tests for patients kind of in their acute stage, you know, stage one and surveillance, stage two, post-RPLND, receiving chemotherapy. And essentially this is a universal germ cell tumor specific biomarker, except for teratoma, suffice it to say 90% sensitive and specific. And I think it's going to change the way that we diagnose and manage patients. You know, pre-orchiectomy, that's pretty straightforward. Post-orchiectomy, maybe we can really decrease the number of CT scans that are done. Maybe we can identify those patients that basically have occult disease where we can intervene early, either with RPLND or single cycle chemo. Post-RPLND, identify the patients who are at higher risk of relapse that may benefit from some adjuvant therapy. In the advanced setting, look at marker decline for patients in addition to standard tumor markers. Can we modulate their systemic therapy?  So, the international interest is largely on modifying things. There's really cool clinical trials that we have for stage one patients, that treatment would be prescribed based on a post-orchiectomy microRNA. I think the microRNAs are really exciting. Teratoma remains an outstanding question. I think this is where maybe ctDNA, perhaps some radiomics and advanced imaging processing and incorporating AI may allow us to safely avoid a lot of these post-chemo RPLNDs. And then identification using SNPs and so forth of who might be most susceptible to some of the cardiac toxicity, autotoxicity and personalizing things in that way as well. Dr. Pedro Barata: Super exciting, right, what's about to come? And I agree with you, I think it's going to change dramatically how we manage this disease.  This has been a pleasure sitting down with you. I guess before letting you go, anything else you'd like to add before we wrap it up? Dr. Aditya Bagrodia: Yeah, first off, again, just want to thank you and ASCO for the opportunity. And it's easy enough to, I think, approach a patient with the testicular germ cell tumor as, "This is an easy case. We're just going to do whatever we've done. Go to the guidelines that says do X, Y, or Z." But there's so much more nuance to it than that. Getting it done perfectly, I think, is mandatory. Whatever we do is an impact on them for the next 50, 60, 70 years of their life. And I found the germ cell tumor community, people are really passionate about it. If you're ever uncertain, there's experts throughout the country and internationally. Ask somebody before you do something that you can't undo. I think we owe it to them to get it perfect so that we can really maximize the survivorship and the survival like we've been talking about. Dr. Pedro Barata: Aditya, thanks for sharing your fantastic insights with us on this podcast. Dr. Aditya Bagrodia: All right, Pedro. Fantastic. Appreciate the opportunity. Dr. Pedro Barata: And also, thank you to our listeners for your time today. I actually encourage you to check out Dr. Bagrodia's article in the 2025 ASCO Educational Book. We'll post a link to the paper in the show notes. Remember, it's free access online, and you can actually download it as well as a PDF. You can also find on the website a wealth of other great papers from the ASCO Educational Book on key advances and novel approaches that are shaping modern oncology.  So with that, thank you everyone. Thank you, Aditya, one more time, for joining us. Thank you, have a good day. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:         Dr. Pedro Barata  @PBarataMD   Dr. Aditya Bagrodia @AdityaBagrodia Follow ASCO on social media:         @ASCO on X (formerly Twitter)         ASCO on Bluesky        ASCO on Facebook         ASCO on LinkedIn         Disclosures:      Dr. Pedro Barata:  Stock and Other Ownership Interests: Luminate Medical  Honoraria: UroToday  Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon  Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas  Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck   Dr. Aditya Bagrodia: Consulting or Advisory Role: Veracyte, Ferring  

Lynne's specialty, developmental pediatrics, is all about how infants and children develop and is closely related to neurology in many cases. So, when she read about a case of an infant with a head circumference too big for the baby's age, it took her right back to her clinical training. However, the cause of the enlargement was not what she expected. This week, Lynne will discuss the unusual phenomenon in which one fetus absorbs another.    Special note: Dr. Helen Shui is truly a doctor, but is working under a pseudonym for privacy reasons. Dr. Lynne Kramer is using her real name.  Music by Helen Shui and Caplixo. Cover art by Lynne Kramer.  Sources: Intracranial Parasitic Fetus in a Living Infant: A Case Study with Surgical Intervention and Prognosis Analysis by Xuewei Qin, Xuanling Chen, Xin Zhao, Bo Wang, Lan Yao, Hongchuan Niu Teaching NeuroImage: Intraventricular Fetus-in-Fetu With Extensive De Novo Gain in Genetic Copy Number by Zongze Li, MD, Li Ma, MD, PhD, Yuanli Zhao, MD, PhD, and Chunde Li, MD Girl, 1, is found to have a FETUS growing in her skull that was once her twin sister by  Maiya Focht  Fetus in fetu: Review of the literature over the past 15 years by Lindsey M. Prescher, William J. Butler, Tyler A. Vachon, Marion C. Henry, Thomas Latendresse, Romeo C. Ignacio Jr. Fetus in fetu – a rare developmental anomaly by Della Harigovind, Harish Babu SP, Sunil V Nair, Nazim Sangram Fetus in Fetu: Lessons Learned from a Large Multicenter Cohort Study by Heba M. A. Taher et. al.  Fetus-in-fetu by Philippe Jeanty, MD, PhD Kay Caldwell, RDMS Patricia Dix, MD Monochorionic Diamniotic Twin Gestations by Karin M. Fuchs, Mary E. D'Alton Monochorionic Twins via Wikipedia Embryology, Week 1 by Yusuf S. Khan; Kristin M. Ackerman. Embryology, Week 2-3 by Baryiah Rehman; Maria Rosaria Muzio. Teratoma via Cleveland Clinic Data Table of Infant Head Circumference-for-age Charts via CDC Website Please contact us with questions/concerns/comments at defunctdoctorspodcast@gmail.com. @defunctdoctorspodcast on Instagram, Facebook, X (Twitter), Threads, YouTube, and TikTok  Follow Lynne on Instagram @lynnedoodles555

Links: Get the Genate Test by SNP Therapeutics, learn more at genate.com and use code BIRTHHOUR15 for 15% off your order. Know Your Options Online Childbirth Course (code 100OFF for $100 off) Beyond the First Latch Course (also comes free with KYO course) Support The Birth Hour via Patreon!

Historically a range of psychiatric and medical conditions have been erroneously attributed to 2 gynecological organs/function. During the time of Hippocrates, the “wandering womb” theory blamed emotional disturbances in women on this condition. Not only was that erroneous, it was nonsensical. However, certain gynecological conditions can indeed manifest with neuro-behavioral disturbances. One of these syndromes can be triggered by the presence of an ovarian dermoid. Anti-N-methyl-D-aspartate receptor (NMDA-R) encephalitis is a paraneoplastic limbic syndrome which may be caused by ovarian teratomas containing neural components. Neural tissue in a teratoma can trigger the production of anti-NMDA-R antibodies, which causes neuronal dysfunction and loss by altering the neuronal cell-surface NMDA receptors in the limbic system. This syndrome presents with a range of psychiatric, neurological and autonomic features and if not promptly recognized and treated may be associated with long-term morbidity and mortality. Rare…yes. But it is out there in the community and patients are at HIGH risk of misdiagnosis. In this episode we will discuss this “Brain on Fire” syndrome and highlight a real case contributed by one of our podcast family members (HIPPA protected).  

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Teratoma from the Oncology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

Today, the fellas are joined by Madeline Tweel, who has rare Ovarian Teratoma-Related Paraneoplastic Neurological Syndrome. Don't worry if you can't pronounce that, Jeremie will do it for ya. Madeline was halfway through medical school when she became a very sick patient. She experienced meningitis, insane headaches, and even had to resort to self-catheterization. And get this, her grandparents gave her tips and tricks over lunch. I mean, who wouldn't want to learn how to self-catheterize over a coffee and a sandwich? Join the post-episode conversation over on Discord! https://discord.gg/expeUDN

Today, the fellas are joined by Madeline Tweel, who has rare Ovarian Teratoma-Related Paraneoplastic Neurological Syndrome. Don't worry if you can't pronounce that, Jeremie will do it for ya. Madeline was halfway through medical school when she became a very sick patient. She experienced meningitis, insane headaches, and even had to resort to self-catheterization. And get this, her grandparents gave her tips and tricks over lunch. I mean, who wouldn't want to learn how to self-catheterize over a coffee and a sandwich? Join the post-episode conversation over on Discord! https://discord.gg/expeUDN

In 2014, David and Chalece Neilsen were eagerly awaiting the arrival of their baby when it was discovered that their little girl suffered from a rare form of cancer. She was born prematurely at 25 weeks and given the name Allison Faith. After a fortnight in a NICU incubator under excellent doctor care, the Neilsens' held their baby for the first and last time as she passed away. The couple each mourned in their own way, leaning heavily on the support of friends and family. And as they continued to struggle with infertility issues, they discovered that Resiliency is not what we think. They join this episode of Relentlessy Resilient to share how it is worth fighting for resilience and peace in the hardest of trials. Even though we live in challenging times we can become Relentlessly Resilient as we lean on and learn from one another's experiences. Hosts Jennie Taylor and Michelle Scharf are no strangers to overcoming adversity; Michelle lost her husband to cancer, while Jennie's husband Major Brent Taylor was killed in the service of our country. Their stories bond them together and now listeners can join them weekly as they visit with others enduring challenges and who teach us how they are exercising resiliency, finding value in their grief, and purpose in moving forward.  Listen to the Relentlessly Resilient Podcast regularly on your favorite platform, at kslpodcasts.com, kslnewsradio.com, or on the KSL App. Join the Resilience conversation on Facebook at @RelentlesslyResilient and Instagram @RelentlesslyResilientPodcast. Produced by KellieAnn Halvorsen.See omnystudio.com/listener for privacy information.

CardioNerds Cofounder Dr. Amit Goyal is joined by an esteemed group of UCLA cardiology fellows – Dr. Patrick Zakka (CardioNerds Academy Chief), Dr. Negeen Shehandeh (Chief Fellow), and Dr. Adrian Castillo – to discuss a case of primary cardiac angiosarcoma. An expert commentary is provided by Dr. Eric Yang, beloved educator, associate clinical professor of medicine, assistant fellowship program director, and founder of the Cardio-Oncology program at UCLA.   Case synopsis: A female in her 40s presents to the ED for fatigue that had been ongoing for approximately 1 month. She also developed night sweats and diffuse joint pains, for which she has been taking NSAIDs. She was seen by her PCP and after bloodwork was done, was told she had iron deficiency so was on iron replacement therapy. Vital signs were within normal limits. She was in no acute distress. Her pulmonary and cardiac exams were unremarkable. Her lab studies showed a Hb of 6.6 (MCV 59) and platelet count of 686k. CXR was without significant abnormality, and EKG showed normal sinus rhythm. She was admitted to medicine and received IV iron (had not consented to receiving RBC transfusion). GI was consulted for anemia work-up. Meanwhile, she developed a new-onset atrial fibrillation with rapid ventricular response seen on telemetry, for which Cardiology was consulted. A TTE was ordered in part of her evaluation, and surprisingly noted a moderate pericardial effusion circumferential to the heart. Within the pericardial space, posterior to the heart and abutting the RA/RV was a large mass measuring approximately 5.5x5.9 cm. After further imaging work-up with CMR and PET-CT, the mass was surgically resected, and patient established care with outpatient oncology for chemotherapy.  CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Case Media - primary cardiac angiosarcoma Episode Schematics & Teaching Pearls – primary cardiac angiosarcoma The pericardium is composed of an outer fibrous sac, and an inner serous sac with visceral and parietal layers.   Pericardial masses can be primary (benign or malignant) or metastatic. There are other miscellaneous pericardial masses.  Imaging modalities for the pericardium include echocardiography, cardiac CT and cardiac MRI. There is also role for PET-CT in pericardial imaging for further characterization of pericardial masses.   Cardiac angiosarcomas are extremely rare but are the most common cardiac primary malignant tumors.  Evidence-based management if lacking because of paucity of clinical data given the rarity of cardiac angiosarcomas. Surgery is the mainstay of therapy. Radiotherapy and chemotherapy are often used as well.  Notes – primary cardiac angiosarcoma Pericardial Anatomy  The pericardium is a fibroelastic sac composed of two layers.   Outer layer: fibrous pericardium (

This week Candice gives us all the gruesome details of teratomas (starts at (10:12)) and Deanna talks about the injustice done to Guy Heinze Jr (the Glynn County Mass Murders) (starts at (28:21)) CHECK OUT our new merch store!  Please remember to subscribe and rate us/review us! Follow us on Instagram! Become a patron and support us via Patreon! Email us your f*cked up stories at NFWpodcast@gmail.com we'd love to hear from you! C U Next Tuesday!

Welcome to another episode of Spooky Gay Bullsh!t, our new weekly hangout where we break down all of the hot topics from the world of the weird, the scary, and issues that affect the LGBTQIA2+ community! This week, we cover: thieves seize a box of heads, an allegedly life-ruining haunted painting, finding Brittney Griner, an Australian jogger stumps the internet with a mystery creature find, and in a very 2020's move, the Killing Stone has split. See you next Friday for more Spooky Gay Bullsh!t! Join the Secret Society That Doesn't Suck for exclusive weekly mini episodes, livestreams, and a whole lot more! patreon.com/thatsspooky Get into our new apparel store and the rest of our merch! thatsspooky.com/store Check out our website for show notes, photos, and more at thatsspooky.com Follow us on Instagram for photos from today's episode and all the memes @thatsspookypod We're on Twitter! Follow us at @thatsspookypod Don't forget to send your spooky gay B.S. to thatsspookypod@gmail.com

Welcome to the Horror Project Podcast. Join hosts Phil and Laura as they review James Wan's Malignant (2021).We discuss our admiration for James Wan, his ambition in wanting to create something original for the horror genre. We also delve into Annabelle Wallis' performance and of course the bonkers places that this film takes us. The ultimate head scratcher of a film certainly left Laura bewildered after a first viewing! So many questions, so little time...Plus we shall be finding a place on the leaderboard for the movie during our Ranking.   Thanks for listening!Email - Horrorprojectpodcast@hotmail.com  Twitter - @TheHorrorProje1Instagram - horrorprojectpodcastTikTok - @horrorprojectpodcast

In this episode, I discuss   What are the psychosomatics of Teratoma TumorYou can find out SO MUCH more from my book Metaphysical Anatomy Volume 1, which is a step-by-step guide for identifying the psychosomatic pattern related to 679 medical conditions. These conditions can be activated by circumstances in your present life, your ancestry, conception, womb, birth trauma, childhood, or adult life. It builds on existing work from many famous authors, making it much more practical, more specific, detailed, and ultimately much more effective! This book is equally valuable for experienced alternative practitioners and those interested in self-healing. You will love this book and the Healing Technique MAT.www.metaphysicalanatomy.com | www.evettebooks.com

TERATOMA was the winner of BEST FILM at the October 2021 HORROR Underground Film Festival. You can watch this film and the festival for FREE on Saturday all day HERE: https://festivalforhorror.com/horror-film-festival/ “Two young people, a girl and a boy, will have to face a venereal disease after having sexual relations.” Conversation with director/writer Jano Pita on the making of the film. Subscribe to the podcast: https://twitter.com/wildsoundpod https://www.instagram.com/wildsoundpod/ https://www.facebook.com/wildsoundpod

Flo und Burger schauen i.S. eines Round-Ups zurück auf das Fright Nights und besprechen Genre-Giganten wie Titane und Halloween Kills. Minimally Invasive - (06:25); Teratoma - (08:30); The Commitment - (10:40); Relaxing with Draco - (12:50); Hexercise - (13:50); Escalation - (17:20); Der Wolf - (18:30); Princesses do as they please - (22:50); Titane - (26:10); The White Goddess - (34:00); Halloween Kills - (37:55). All music and clips are used under the fair use predicate.

In this episode, I discuss  What are the psychosomatics of Teratoma TumorYou can find out SO MUCH more from my book Metaphysical Anatomy Volume 1, which is a step-by-step guide for identifying the psychosomatic pattern related to 679 medical conditions. These conditions can be activated by circumstances in your present life, your ancestry, conception, womb, birth trauma, childhood, or adult life. It builds on existing work from many famous authors, making it much more practical, more specific, detailed, and ultimately much more effective! This book is equally valuable for experienced alternative practitioners and those interested in self-healing. You will love this book and the Healing Technique MAT.www.metaphysicalanatomy.com | www.evettebooks.com

Thanks for coming back as we close out the the 2nd half of the Malignant movie review! Tut & Ms. B definitely has some things to say about this one. #DontGoInThereGirl #Malignant #DGITGPod #Horror #HorrorMovies #ScaryMovies #MsB #Tut #MovieReview #ScaryShit # #Podcast #Spotify #AnchorFM #ApplePodcasts #Overcast #GooglePodcasts #Castbox #Breaker #PocketCasts #RadioPublic --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/letitia-carter/message

Looks like James Wan (The Conjuring, Insidious, Saw) came and directed a film that is very different and unique in the horrorsphere. Join your favorite Horror Aunties, Ms. B & tut, as we go down the path of a woman being haunted and tormented by a series of shocking visions; visions that may be her own terrifying reality. But why her? Why has she been chosen to involuntarily bear witness all of these atrocities? Grab your popcorn as we go through the back-bends, twists & turns of this review. It's gonna be a good one! #DontGoInThereGirl #Malignant #DGITGPod #Horror #HorrorMovies #ScaryMovies #MsB #Tut #MovieReview #ScaryShit # #Podcast #Spotify #AnchorFM #ApplePodcasts #Overcast #GooglePodcasts #Castbox #Breaker #PocketCasts #RadioPublic --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/letitia-carter/message

Nesta edição, o Dr. José Roberto Portante explica a denominação, os tipos, os aspectos, o diagnóstico e a forma de tratamento contra o teratoma, tumor formado por vários tipos de células germinativas, ou seja, células que, após se desenvolverem, podem dar origem a diferentes tipos de tecidos do corpo por humano.

The All Spoiler Recap is back ... for real this time! Per your request, Episode 76 takes you through the bonkers is-it-a-dream-or-is-it-reality plot of the 2021 horror film MALIGNANT. Complete the journey with Julia Cunningham and her guest, Joe Navarre. 

#578 - Teratoma Homunculus What is it? Find out on today's deep dive into the internet with Mikey Boohyah and William Waffles. Or just google it yourself. We also play Jeopardy. Look, to be honest, I'm in Vegas right now and having a hard time remembering what we did on this episode so click play and we'll find out together. Ok... I'm hanging up, now. Bye!

Episode 43: Testicular Cancer. Testicular cancer screening and diagnosis (basics), chlorthalidone vs hydrochlorothiazide, and jokes.Today is March 8, 2021. For many years, we have heard about the superiority of chlorthalidone over hydrochlorothiazide to control hypertension, but in clinical practice, hydrochlorothiazide is prescribed more often as the initial therapy for most patients with hypertension as compared to chlorthalidone. As a matter of fact, the Microsoft Word automatic corrector detects hydrochlorothiazide as a correct word, but flags chlorthalidone as misspelled. Also, we know how to abbreviate hydrochlorothiazide (HCTZ), but did you know that chlorthalidone has an abbreviation as CTD?We have been neglecting chlorthalidone regardless its apparent effectivity.  In January 2006, the American Heart Association published on its journal Hypertension, a comparison between chlorthalidone and hydrochlorothiazide to control hyperension[1]. A randomized, single-blinded, 8-week active treatment, crossover study compared 12.5mg/day chlorthalidone (force-titrated to 25 mg/day at week 4) and HCTZ 25mg/day (force-titrated to 50mg/day at week 4) in untreated hypertensive patients. 24-hour BP monitoring was assessed at baseline and week 8 plus standard office BP readings every 2 weeks. 30 patients completed the active treatment period.  At week 8 there was a greater reduction in baseline systolic blood pressure with chlorthalidone 25mg vs HCTZ 50mg. The effectiveness of chlorthalidone was evidenced by ambulatory blood pressure measurement (ABPM) although this difference was not apparent with office BP measurements. It was a short duration study with a small sample size.More recently, in January 2021, the Journal of Hypertension, which is the official journal of the International Society of Hypertension and the European Society of Hypertension[2], published on PDF a more comprehensive review of these long-time rivals. According to the short version of this article, there is no difference in the short-term net clinical benefit between CTD and HCTZ, BUT long-term available data suggests that CTD is better at reducing major adverse cardiovascular events (MACE) over HCTZ. Stay tuned for the final version of this study.Way to go chlorthalidone!______________________________This is Rio Bravo qWeek, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California. Our program is affiliated with UCLA, and it’s sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home.  Page BreakQuestion of the Month: Polyarthralgiaby Claudia Carranza  A 49-year-old female comes to clinic reporting bilateral wrist and ankle pain for 1 month. The pain is worse with movement and responds well to ibuprofen. She denies joint swelling, warmth, or morning stiffness. She reports feeling more fatigued than usual this past month. You note on her chart that she was diagnosed with COVID-19 approximately 6 weeks ago for which she did not need to be hospitalized.  She denies history of diabetes, thyroid disease, lupus, rheumatoid arthritis, trauma, or anemia. She denies fecal, urinary, or vaginal bleeding, no headaches, chest pain, SOB or dizziness. Exam is remarkable for a “tired look” and tenderness to palpation at bilateral wrist and ankles. No signs of inflammation on joints is noted. What do you think is the etiology of this patient’s symptoms and what workup would you order (if any)? Let’s repeat the question: What do you think is the etiology of the symptoms in a 49-year-old female who complains of symmetrical POLYARTHRALGIA and fatigue for 1 month, and what workup would you order (if any)? Clue: Listen carefully to the history of the patient. Send us your answer to rbresidency@clinicasierravista.org before March 22, 2021. The winner will receive a prize.“I am not my body. My body is nothing without me.” Tom Stoppard____________________________Testicular Cancer Testicular cancer is the most common solid tumor among males 15 to 34 years of age, with an estimated 8,850 new cases and 410 deaths in the past years. The good news is that with effective treatment, the overall five-year survival rate is 97%[3]. Risk factors. Cryptorchidism: The relative risk of developing testicular cancer ranges from 2.9 to 6.3; the risk is increased in both testes, although the risk is much higher in the ipsilateral testis (6.3 vs. 1.7). Among these patients, the risk of cancer increases when orchiopexy is delayed until after puberty or never performed compared with early orchiopexy. Even after early orchiopexy, the risk of testicular cancer remains elevated compared with the general population.  Personal or family history of testicular cancer: Patients with a personal history of testicular cancer have a 12-times greater risk of developing a contralateral testicular cancer than the general population. However, the greatest risk is in the first five years after diagnosis. Patients with a father or brother with testicular cancer have a 3.8- and 8.6-times greater risk, respectively. Infertility: Men with infertility have an increased risk of testicular cancer, with a standardized incidence ratio of 1.6 to 2.8, although the underlying mechanism is unclear. HIV: Human immunodeficiency virus infection/AIDS increases the risk of seminoma, but this is negated with highly active antiretroviral treatment.  Inconclusive risk: Associations between testicular cancer and marijuana use, inguinal hernia, diet, maternal smoking, and body size are inconclusive.  Not a risk factor: Testicular microlithiasis, vasectomy, and scrotal trauma are not risk factors for testicular cancer. Screening for testicular cancer. The U.S. Preventive Services Task Force, National Cancer Institute, and American Academy of Family Physicians recommend against screening for testicular cancer (by a clinician or through self-examination) in asymptomatic adolescents and adults because of its low incidence and high survival rate. The American Cancer Society states that a testicular examination should be part of a routine cancer-related checkup but does not include a recommendation on regular testicular self-examinations for all men.Assessment of suspected testicular cancer patient.History and physical exam are the foundation for the diagnosis. Men with symptoms should receive a complete history and physical examination. Scrotal ultrasonography is the preferred initial imaging study. Testicular cancer may present as a painless scrotal mass, an incidental radiologic finding, posttraumatic symptom, or scrotal pain. Less commonly, presenting symptoms may indicate metastatic disease.  Symptoms of testicular cancer include scrotal symptoms such as acute pain in the testis or scrotum, scrotum or abdomen discomfort or aches, painless mass of the testis, scrotal heaviness and swelling. Symptoms related to metastasis are non-specific and depend on the location of metastasis, including dyspepsia, abdominal pain or discomfort, gynecomastia, headaches, low back pain, neck mass, chest pain, cough, dyspnea, and hemoptysis.Testicular changes may be detected by the patient or by a sex partner. Epididymitis is an important part of the differential diagnosis of a scrotal mass.The normal testis is 3.5 to 5 cm in length, smooth, homogenous, movable, and detached from the epididymis. Hard, firm, or fixed areas within or adjacent to the testes are abnormal and warrant further evaluation. Physical examination should also include evaluation of the inguinal and supra-clavicular lymph nodes, the abdomen, and the chest for gynecomastia (related to tumor secretion of beta human chorionic gonadotropin). If a solid intratesticular mass is discovered, orchiectomy is both diagnostic and therapeutic. Imaging.Scrotal ultrasonography is the preferred initial imaging study for evaluating a testicular mass.Ultrasonography has a sensitivity of 92% to 98% and specificity of 95% to 99.8%. A solid intratesticular mass on ultrasonography warrants rapid referral for radical inguinal orchiectomy because this procedure provides pathologic diagnosis and is the cornerstone of treatment.Staging. Staging through chest radiography, chemistry panel, liver function tests, and tumor markers guides treatment. Active surveillance, chemotherapy, retroperitoneal lymph node dissection, and radiation therapy are treatment options following orchiectomy. For patients desiring future fertility, sperm banking should be discussed early in the course of treatment. Treatment. Radical inguinal orchiectomy, including removal of the spermatic cord to the internal inguinal ring, is the primary treatment for any malignant tumor found on surgical exploration of a testicular mass. Testis-sparing surgery is generally not recommended but may be performed for a small tumor in one testis or for small bilateral tumors. Orchiectomy may be delayed if life-threatening metastases require more urgent attention. The risk of testicular cancer recurrence is greatest within two to three years of primary treatment, and surveillance is continued for up to five years.Classification of Testicular Tumors: Germ cell tumors (95% of all testicular cancers)Derived from germ cell neoplasia in situSeminomaNonseminoma (nonseminomatous germ cell tumors)Embryonal carcinomaYolk sac tumor (postpubertal)Trophoblastic tumors (e.g., choriocarcinoma, placental site trophoblastic tumor)Teratoma (postpubertal) with or without malignant transformationMixed and unclassified germ cell tumorsNot derived from germ cell neoplasia in situSpermatocytic tumorTeratoma (prepubertal)Yolk sac tumor (prepubertal)Sex cord–stromal tumors (< 5% of all testicular cancers)Leydig cell tumorSertoli cell tumorGranulosa cell tumorMixed and unclassified sex cord–stromal tumorsMixed germ cell and stromal tumors (proportion of all testicular cancers not well defined) GonadoblastomaMiscellaneous tumors (proportion of all testicular cancers not well defined) Ovarian epithelial-type tumors Hemangioma Hematolymphoid tumors Tumors of the collecting duct and rete testis (adenocarcinoma)Differential diagnosis of testicular cancer.Tip 1: Testicular torsion is one of the most important differential diagnosis of testicular cancer. Testicular torsion is an emergency, and the presentation is quite different than cancer as it presents with acute, sudden, severe, unilateral testicular pain. Patients are very apprehensive to the exam. The scrotum may appear discolored and swollen; and the affected testicle is typically horizontal and at a higher position than expected in the scrotum. The treatment is surgical. In isolated areas, where surgery cannot be performed in a 2-hour period, a manual testicular detorsion can be attempted with appropriate analgesia and/or sedation. Try to rotate the affected testicle twice, 360 degrees, from medial to lateral. A “drop” of the testicle in the scrotum is felt with relief of pain. One-third of patients need detorsion to the opposite direction, from lateral to medial instead. Tip 2: Epididymitis presents as a pain for about 1-2 weeks. Tenderness is located behind the testicle and patient may complain of dysuria as well. Perform a urine test or urethral swab for gonorrhea and chlamydia. In patients younger than 35, consider empiric treatment while you wait for the results with ceftriaxone PLUS doxycycline or azithromycin. In patients older than 35, consider gram negative coverage with levofloxacin or trimethoprim-sulfamethoxazole. Tip 3: Consider other causes of infection in testis or scrotum, including viruses such as mumps (in unvaccinated populations) and even tuberculosis. If you are curious, read my article about it in PubMed titled “A Case of Testicular Granulomatous Inflammation Mistaken for Malignancy: Tuberculosis Identified Post Orchiectomy”[4].  Tip 4: Epidydimal cyst, spermatocele, and hydrocele are asymptomatic or minimally symptomatic, they are not located in the testis, but you can palpate a distinctive mass posterior or higher than the testis. You can try transillumination of these masses, and they should be translucent. Confirm with testicular ultrasound if in doubt. Tip 5: A testicular hematoma can happen after blunt trauma, but don’t be fooled by the history of traumas as up to 10% of testicular cancers may be discovered after trauma. Perform ultrasound and tumor markers to establish a diagnosis. Tip 6: A scrotal hernia may cause concerns in a patient. Clinically, the inguinal canal appears full and the mass in the scrotum is reported to improve with rest. If the mass is exquisitely tender and not reducible, emergent evaluation by surgery is warranted to rule out hernia strangulation, especially if scrotal pain is accompanied by abdominal distension, abdominal pain, nausea, and vomiting.        ____________________________For your Sanity: Jokesby Anonymous Medical AssistantsHow does a deaf gynecologist communicate? They read lips!How do you get a squirrel to like you? Act like a nut.Why did the math book look so sad? It had a lot of problems.Why can’t a nose be 12 inches long? Because then it’d be a foot.What’s brown and sticky? A stick.Why did the rope go to the doctor? Because it had a knot on the stomach.Why did the mattress go to the doctor? Because it had Spring fever. Now we conclude our episode number 43 “Testicular cancer”, marking our podcasts one year anniversary!. Dr. RAVA covered the recommendations given by USPSTF and the American Cancer Society regarding screening for testicular cancer. Screening in asymptomatic adults is mostly not recommended but it can be a part of a cancer-related checkup. As part of our introduction today, we mentioned effective chlorthalidone is in preventing major adverse cardiovascular events. Our question of the month is still on, and we look forward to reading your answers. The question is: What is the etiology of polyarthralgia in a 49-year-old woman with pain on wrists and ankles for 1 month, and what work up would you order (if any)? The listener who sends the best answer will win a prize! Remember, even without trying, every night you go to bed being a little wiser.Thanks for listening to Rio Bravo qWeek. If you have any feedback about this podcast, contact us by email RBresidency@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. This podcast was created with educational purposes only. Visit your primary care physician for additional medical advice. This week we thank Hector Arreaza, Valerie Civelli, Sapna Patel, Manjinder Samra, Dr. RAVA, and voluntarily-unidentified medical assistants. Audio edition: Suraj Amrutia. See you next week! _____________________References:Roush, George C.a; Messerli, Franz H. Chlorthalidone versus hydrochlorothiazide, Journal of Hypertension: January 19, 2021 - Volume Publish Ahead of Print - Issue - doi: 10.1097/HJH.0000000000002771. https://journals.lww.com/jhypertension/Abstract/9000/Chlorthalidone_versus_hydrochlorothiazide__major.96738.aspx Ernst, Michael E., Barry L. Carter, Chris J. Goerdt et al., American Heart Association, Hypertension, Volume 47, Issue 3, 1 March 2006, Pages 352-358, https://doi.org/10.1161/01.HYP.0000203309.07140.d3 Baird DC, Meyers GJ, Hu JS. Testicular Cancer: Diagnosis and Treatment. Am Fam Physician. 2018 Feb 15;97(4):261-268. PMID: 29671528. https://www.aafp.org/afp/2018/0215/p261.html Civelli VF, Heidari A, Valdez MC, Narang VK, Johnson RH. A Case of Testicular Granulomatous Inflammation Mistaken for Malignancy: Tuberculosis Identified Post Orchiectomy. J Investig Med High Impact Case Rep. 2020 Jan-Dec;8:2324709620938947. doi: 10.1177/2324709620938947. PMID: 32618206; PMCID: PMC7493239. https://pubmed.ncbi.nlm.nih.gov/32618206/

It is one of our favorite times of the year, Halloween! SCR wants to celebrate with a fun Halloween themed interview with melodic metal band Dematus. Matthew wore a top hat and chatted with the band about their favorite Halloween movies and stories, filming the music video for Teratoma, future plans for Dematus, and so much more! There is even an appearance from a pig in this interview. Check out this fun and spooky interview and please stream, support, and give a like to Dematus! SCR and Matthew Thomas would like to thank Jessica, Ryan, Brian, and Dakota of DI Records for making this interview possible! Have a great Halloween everyone! Music credit to Story Block Audio for G Minor Electric Piano Halloween Loop https://www.storyblocks.com/audio --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/supercoolradio/support

On this episode Vadis and I were joined by producer Starblade to break down his new EP Teratoma! We talked all things music, and laid down the challenge for his next appearance on EDM Obscura.... I hope you are enjoying the pod, please leave some reviews and subscribe for new episodes every week! AND... if you'd like to be a guest, please reach out to me on Discord or at EDMObscura@gmail.com I'm always looking for new talent to chat with and help bring out of obscurity.

Is it possible to grow a tumor with teeth? And how could it happen?And what is dissociative identity disorder?Find out the answers to these questions and more on today's episode of Facts-Chology on Teratomas and Dissociative Identity Disorder.Thank you for listening, please subscribe, rate, and review!Sourceshttps://www.theguardian.com/commentisfree/2015/apr/27/teratoma-tumour-evil-twin-cancerhttps://www.healthline.com/health/teratomahttps://en.wikipedia.org/wiki/Teratomahttps://www.psychologytoday.com/us/conditions/dissociative-identity-disorder-multiple-personality-disorder#:~:text=Dissociative%20identity%20disorder%20(DID)%20is,as%20an%20experience%20of%20possession.https://www.webmd.com/mental-health/dissociative-identity-disorder-multiple-personality-disorder#2https://en.wikipedia.org/wiki/Dissociative_identity_disorderSupport the show (https://www.patreon.com/user?u=38292508)

Stillborn… and 3 months premature, Jamie Moore miraculously survived a Teratoma Tumor growing on her lower spine while she was developing in her mother's womb. Discover her journey from doctors predicting she would be in a vegetative state for life to going on to marriage and raising two healthy, active, and growing boys! If you would like to share your Story Of Hope or become a sponsor of a future episode, email me today at: Christine@storysofhope.com --- Send in a voice message: https://anchor.fm/storiesofhope/message Support this podcast: https://anchor.fm/storiesofhope/support

Everything To Guppy is a bite-sized, four-times weekly comedy/gaming podcast in which Gary Butterfield (Watch Out For Fireballs) and William Hughes (The A.V. Club) attempt to analyze every single item, boss, character, and concept in the rogue-lite video game The Binding Of Isaac. They manage to pull it off only slightly less than 50 percent of the time.

This week Mr. Funny Bones himself Mike Colby from Jack Billings Presents: Me and My Neighbor Michael joins Terrie for another hilarious episode. They talk about "Mad Balls" looking tumors. What would you think if a doctor pulled out a tumor with hair, teeth and bone? Is a Teratoma a twin? Did you know that Teratoma's are the misbehaving Stem Cells in our bodies. Are Teratoma's tumors alive? They dive into scientific information on this weird bodily "Monster". Drunk Medical StoriesTwitter: @dmspodFacebook: Drunk Medical Stories PodcastIG: Drunk Medical StoriesEmail: dmspodcast@yahoo.com

Join us on another episode of I'm Horrified where we breakdown a historical lady and something you totally didn't want to know existed! This week, we're talking about the life of Lady Caroline Lamb, Byron's jilted ex. We then deep dive into Teratoma and learn a bunch of information you won't be able to unhear. Break out your quill, marvel at the human body, and Stay Horrified!

Sarah's boob is bleeding and she doesn't know why, Calle's mystery illness lands her on The Megyn Kelly Show  With shameful medical mystery stories from Sarah Squirm (@SarahSquirm) and Calle Hack (@CalleHack)  Check out westilllikeyou.com to find out how you can watch the show live! Support the show on Patreon! https://www.patreon.com/WeStillLikeYou Check out Sarah's insane Adult Swim infomercial: https://urlzs.com/aWA8

Follow us on Facebook: Snews You Lose Twitter: snewsyoulose1 --- Send in a voice message: https://anchor.fm/Snewsyoulose/message

Teratomas are a unique type of tumor that are best known for containing human teeth and hair. Let's discuss the history of these tumors, and how those teeth and hair end up inside them.   We are sponsored by: ThinkGeek and Audible.com  Want to donate? Go to the MCP Website or our Patreon page

LINKS BELOW! FlightOfIcarus interviews Buffalo, NY band INERTIA and shares clips from their new album Teratoma along the way. We talk about their highly eclectic style, varied list of influences, technical training, and reminisce about discovering new music at record stores. Be sure to pick up their album on Bandcamp at the Price Of Your Choosing: https://inertiametalny.bandcamp.com/album/teratomaFacebook: https://www.facebook.com/inertiametalny/Don't forget to SUBSCRIBE, like, comment, rate, etc. Find more over at MetalTrenches.com. We are also available on iTunes, BitChute, and CastBox.Become a Patron! https://www.patreon.com/metaltrenchesReview and Full Album Stream:Inertia: https://metaltrenches.com/reviews/teratoma-1749Shout Outs:Short Attention Span Theater: https://shortattentionspantheatre.bandcamp.com/Ish Kabbible: https://lowtonesofhome716.bandcamp.com/track/ish-kabbible-s-d-fTorrential Downpour: https://torrentialdownpour.bandcamp.com/album/truth-knowledge-visionConnect:https://metaltrenches.comhttps://metaltrenches.bandcamp.com/https://twitter.com/MetalTrencheshttps://www.instagram.com/metal.trenches/SUBSCRIBE TO OUR NEWSLETTER: http://eepurl.com/dogQCDTheme Song: The Hudson Horror – “What The Moon Brings”Support the show (https://www.patreon.com/metaltrenches/creators)

Sean and Jessica talk about Jessica and the happy fun time she's had over the last month including being robbed and having a teratoma tumor as an uninvited holiday guest.

Non seminomatous germ cell tumours including embryonal carcinoma, teratoma and yolk sac tumours. 

A brief overview of germ cell tumours of the testis

LENGTH: 30:00 GUESTS: Ali Mahajani, Andy Melton, Dace SYNOPSIS Part II-Andy & Dace join Rill and Ali. Losing weight but no scale? Measure neck! Teratoma in lapse and other shit. PLUS an oldie but goodie-RillSings HeyHonaye (dedicated turd TrannyWreck)! Why … Continue reading →